**Core tip:** The Gallbladder cancer is a fatal malignancy which displays considerable differences in certain ethnicities and geographic regions. Indo-Gangetic plains of India, Mapuche Indians in Chile and South America are most affected regions with this cancer. Because of this cancer is largely unstudied as compare to other cancers Present review provides a comprehensive summery of the studies conducted regarding its Epidemiology, Pathogenesis and molecular genetics. This will be helpful for the researchers to understand the current scenario of research work and how much success we have gained till now. Based on which future research work can be planned in appropriate directions.

INTRODUCTION
============

Gallbladder cancer (GBC) is a rare biliary tract malignancy in most western countries, but is much widespread in some other regions of the world. Moreover, this carcinoma is infrequent in developed countries but more common in some developing countries, characterized by its lack of symptoms at initial stage leading to difficulties in treatment.

The extensive variation in geography, ethnicity, and cultural differences in the incidence of gallbladder cancer suggests the role of key genetic and environmental factors associated with the development and progression of the disease\[[@B1],[@B2]\]. The lack of a serosal layer of gallbladder adjacent to the liver thus enabling hepatic invasion and metastatic progression is one of the major cause of its miserable prognosis\[[@B3]\]. The present review provides a recent update of studies regarding epidemiology, pathogenesis and molecular genetics of gallbladder cancer as available in literature.

EPIDIMIOLOGY OF GALLLBLADDER CANCER
===================================

Gallbladder cancer shows an unusual geographic distribution worldwide with substantial geographic variation. Data from Mapuche Indians from Valdivia, Chile, South America shows the rate of gallbladder cancer as: 12.3/100000 for males and 27.3/100000 for females\[[@B3]\]. The native people is these countries exceed for gallbladder cancer mortality rates from cervical (8.0/100000), breast (8.7/100000), pancreatic (7.4/100000), and ovarian cancers (7.3/100000)\[[@B3]\]. American Indians in New Mexico, USA, have also very high average annual rate of GBC (8.9/100000)\[[@B4]\], \[Surveillance, Epidemiology End-Results Program (SEER) The Four Most Common Cancers for Different Ethnic Populations 2013. Bethesda, MD: National Cancer Institute; 2013\].

Although the worldwide occurrence of gallbladder cancer is less than 2/100000 individuals, but this has been recorded with extensive variance\[[@B5]\]. The residents of Indo-Gangetic belt particularly females of northern India (21.5/100000) and south Karachi Pakistan (13.8/100000) have been reported as one of the highest affected regions\[[@B4]\]. Gallbladder cancer is also found in high frequency in Eastern Europe include Poland (14/100000 in Poland), Czech Republic, and Slovakia and Asia whereas south Americans of Indian descent (3.7 to 9.1 per 100000), Israel (5/100000) and Japan (7/100000) have shown intermediate prevalence of gallbladder cancer\[[@B4],[@B6]\]. The residents of Andean-area, North American Indians and Mexican-Americans are specially predisposed of GBC\[[@B6]\]. The majority of the world has decreasing mortality trends in gallbladder cancer but GBC frequency is constantly rising in Shanghai, China which is substantial cause of mortality\[[@B7]\]. Although Gallbladder cancer is more common in females still in some countries like Korea, Iceland and Costa Rica, higher mortality rate has been reported for males as compare to females\[[@B8]\]. The data from National Cancer Institute; SEER Program (<http://seer.cancer.gov/>) has revealed only little turn down in incidence over the past few decades.

ETIOLOGICAL FACTORS FOR GBC PATHOGENESIS
========================================

The development of gallbladder cancer has been linked to various genetic and environmental factors. Chronic infection of gallbladder or/and environmental exposure to specific chemicals, heavy metals, and even many dietary factors, have been found to be associated with GBC formation. The dramatic association of GBC with female gender and certain geographical regions (mostly developing countries) has been proposed to be influenced by various female hormones, cholesterol cycling and salmonella infections in existing literature\[[@B9],[@B10]\]. Worldwide GBC affects females 2-3 times more commonly than males, but bias varies greatly in different parts of the world mostly in high prevalent regions of GBC\[[@B4],[@B6]\]. To some extent, the female hormone estrogen causes increased cholesterol super saturation in bile and hence involved in gallstone mediated GBC pathogenesis\[[@B11]\]. Although the female gender GBC can be linked with the role of female hormones. However an article published previously has questioned the association of hormone receptor expression to tumor differentiation\[[@B12]\]. So the extent of female hormones contribution in Gallbladder cancer is still not certain and requires more investigation.

Other well-known GBC associated risk factors such as porcelain gallbladder, Mirizzi's syndrome and bile reflux has also been playing a major role as a predisposing factors of this disease\[[@B9]\]. Family history of gallstones, tobacco consumption, chemical exposure, residence in Gangetic belt and high concentrations of secondary bile acids, excessive intake of fried foods (reused oil), increases the risk for GBC\[[@B13]\]. Present data suggest that gallstones are a major risk factor for GBC but their role as a cause for gallbladder cancer is still not certain. A review article by Shrikhande et al\[[@B14]\] has also supported the fact that the populations reporting high incidence of gallbladder cancer with associated gallstones, prophylactic cholecystectomy should be done only after correlating with the epidemiological profile of the place. Convincing evidence also exists for the presence of gallstones as strongly associated factor for gallbladder cancer etiology\[[@B7]\]. Most of the etiological factors are summarized in Table [1](#T1){ref-type="table"}\[[@B6],[@B7],[@B10],[@B13],[@B15]-[@B50]\].

###### 

Etiological factors for gallbladder cancer pathogenesis

  **Major Independent Etiological factors**                                                                  **Dependent Etiological factors**
  ---------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------
  Age\[[@B6]\]                                                                                               Tobacco consumption\[[@B15]\]
  Sex\[[@B6]\], BMI\[[@B16]\]                                                                                Mustard oil\[[@B17]\] Argemone oil (AO) and butter yellow (BY)\[[@B18]\]
  Family history\[[@B7],[@B19]\]                                                                             Early age at first pregnancy\[[@B20]\]
  Cholelithiasis\[[@B6],[@B22]-[@B24]\]                                                                      Use of Oral contraceptives\[[@B15],[@B25],[@B26]\]
  Chronic cholecystitis, porcelain gallbladder\[[@B27],[@B28]\]                                              Red Chili pepper\[[@B29],[@B30]\]
  Chronic infection by *Salmonella* species, *S. paratyphi* or *S. typhican*\[[@B6],[@B10],[@B31]-[@B34]\]   Occupational exposure, Benzene\[[@B17],[@B35]\]
  *Helocobacter pylori*\[[@B36],[@B37]\]                                                                     Secondary bile acids\[[@B13],[@B38]-[@B40]\]
  High parity\[[@B20],[@B21],[@B24],[@B26]\]                                                                 Xanthogranulomatous cholecystitis\[[@B41]\]
  Anomalous pancreatobiliary duct junction\[[@B42],[@B43]\]                                                  Heavy metals\[[@B44],[@B45]\]
  Porcelain gallbladder\[[@B46]\]                                                                            Genetic factors\[[@B48]\]
  Gallbladder polyp\[[@B47]\]                                                                                
  Obesity\[[@B49]\]                                                                                          Free radical oxidation products\[[@B50]\]

Familial and linkage studies
----------------------------

Swedish family-cancer database and Utah cancer registry has reported the first ever data for familial clustering of GBC\[[@B51]\]. This study has provided the first data on familial clustering of gallbladder cancer based on medically confirmed records, in which it was estimated that 26% of gallbladder cancers are familial. The significant risk in 3^rd^ degree relatives and the disease manifestation in several high risk pedigrees as reported in previous studies gives a strong indication for genetic susceptibility to GBC\[[@B51]\]. The high risk heritable factors are likely to contribute to a large extent to this cancer further modulated by environmental factors. The nationwide Swedish Family-Cancer Data base from the Swedish Cancer Registry (10.2 million individuals from the year 1961-1998), has reported maternal transmission favoring over paternal in familial gallbladder cancers\[[@B52]\]. Furthermore, the clustering of gallbladder cancer within families is suggestive of a critical role of genetics in its development\[[@B19]\]. Carcinoma gallbladder was detected in two siblings from Brazil as reported by Trajber et al\[[@B53]\]. Role of allele specific mutations in pathogenesis of carcinoma gallbladder has also been reported\[[@B54]\]. Another report by Pandey et al\[[@B55]\] has shown higher frequency of carcinoma gallbladder in patients with A+ and AB+ blood groups to which the reason is still unknown.

GENETIC AND MOLECULAR ALTERATION REPORTED IN GALLBLADDER CARCINOMA
==================================================================

The present existing information regarding genetic and molecular alterations in GBC is still very much limited. Like other neoplasms, GBC is a multifactorial disorder involving multiple genetic alterations\[[@B56]-[@B58]\]. Abnormality in tumor suppressor genes, oncogenes, and DNA repair genes, presence of microsatellite instability (MSI) and epigenetic alterations mainly caused by aberrant promoter methylation of gene areas are some of the various well known factors reported till now. The serious of genetic alteration leading to gallbladder cancer formation is still not established clearly. Some of the molecular alterations reported so far are enumerated in Tables [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}.

###### 

Mutations detected in gallbladder cancer by low throughput methods

  **Studied gene**                 **Type of study**                        **Methods used**                     **Studied population**   **Ref**.
  -------------------------------- ---------------------------------------- ------------------------------------ ------------------------ -----------------
  *KRAS*                           Mutation at codon-12 (8%)                PCR-RFLP                             India                    \[64\]
  Mutation at codon-12 (29%-30%)   PCR-RFLP                                 Chile                                \[76,77\]                
  Mutation at codon-12 (0%-59%)    PCR-RFLP, Direct sequencing              Japan                                \[60,78,79\]             
  Mutation at codon-12 (50%-80%)   ELMA, SAB, PCR-SSCP, Direct sequencing   Japan                                \[63,80\]                
  *INK4A (p16)*                    Mutation, deletion                       PCR-RFLP, direct sequencing, IHC     Japan, Chile             \[54,79,81,82\]
  *D310 mtDNA*                     Mutation (Displacement loop)             PCR-based assay, direct sequencing   Chile                    \[83\]
  *TP53*                           Mutation, overexpression, LOH            PCR-RFLP, direct sequencing, IHC     Greece, Japan, Chile     \[84-86\]

###### 

Mutations studies in gallbladder cancer by high throughput methods

  **Platform**                                                  **Number of samples**   **Study population**              **Research planned**                                                   **Key findings**                                                                   **Ref**.
  ------------------------------------------------------------- ----------------------- --------------------------------- ---------------------------------------------------------------------- ---------------------------------------------------------------------------------- ----------
  Sequenom Mass ARRAY technology                                49 FFPE                 India                             390 mutations in 30 genes                                              *PIK3CA* (4%), *KRAS* (2%), *CTNNB1* (4%), *TP53* (18%)                            \[95\]
  Mass spectroscopy-based                                       57 FFPE                 MD Anderson Centre                159 mutations in 33 genes                                              14 hotspot mutations in 9 cases including (*KRAS, NRAS, PIK3CA, IDH1, ALK, MET*)   \[94\]
  26 mutations in 15cases                                                                                                                                                                                                                                                           
  Next-generation sequencing (NGS)                              15 FFPE                 NGS of 182 cancer-related genes   (*P53, STK11, RICTOR,TSC2, FGF3-TACC* fusion, *FGF10* amplification)   \[94\]                                                                             
  Preponderance of mutations involving the PI3 kinase pathway                                                                                                                                                                                                                       
  Whole Exome and transcriptome Sequencing                      29 Fresh Frozen         Japan                             64 non silent mutations signatures                                     *EGFR, ERBB3, PTEN, ARID2, MLL2*,                                                  \[96\]
  *MLL3, APOBEC, TERT*                                                                                                                                                                                                                                                              
  *APOBEC*-associated mutation signature were observed in GBC                                                                                                                                                                                                                       
  Exome sequencing and targeted gene sequencing                 57 Fresh Frozen         China                             Whole exome sequencing                                                 *TP53* (47.1%), *KRAS* (7.8%) and                                                  \[93\]
  *ERBB3* (11.8%)                                                                                                                                                                                                                                                                   
  ERBB pathway genes mostly mutated                                                                                                                                                                                                                                                 

FFPE: Fresh frozen paraffin embedded.

###### 

Summary of global gene expression studies in gallbladder cancer

  **Biological sample used**                                                                                                                 **Platform/studies key findings**                   **Ref**.
  ------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------- ----------
  17 gallbladder tissue specimens (6 advanced GBC , 6 early GBC cancers and 5 normal control                                                 Oligonucleotide Microarray platform                 \[97\]
  Unregulated genes: 2270                                                                                                                                                                        
  Downregulated genes: 2412                                                                                                                                                                      
  5-Normal biliary epithelial scrapings, 11- surgically resected biliary carcinomas, 9-biliary cancer cell lines                             Oligonucleotide Microarray platform                 \[98\]
  Unregulated genes : 282 genes                                                                                                                                                                  
  Downregulated genes: 513                                                                                                                                                                       
  37 biliary tract carcinomas                                                                                                                cDNA array platform                                 \[99\]
  (15 bile duct, 11 gallbladder, 11 of ampulla of Vater)                                                                                     118 genes were identified with a prognostic value   
  12 advanced gallbladder carcinoma tissue 3 samples of normal control gallbladder epithelium                                                Oligonucleotide Array platform                      \[100\]
  Upregulated: (TOPO II-alpha, cyclin B2, CDC28, ubiquitin-conjugating enzyme E2C), and one metabolism-related: (gamma-glutamyl hydrolase)   \[101\]                                             
  34 biliary tract cancers including                                                                                                         Oligonucleotide Array platform                      
  13 intrahepatic (IHC), 12extrahepatic (EHC), 9 (GBC)                                                                                       1281 genes with deregulated expression pattern      

GENETIC ALTERATIONS IN GBC
==========================

KRAS
----

KRAS act as initial key player in numerous signal transduction mechanisms and associated pathways. Many pathogenic mutations have been reported in *KRAS onco*gene in Gallbladder cancer tissue\[[@B58]-[@B63]\]. K*RAS* gene mutations identified in GBC mostly affects codons 12, 13 and 61. In north India *KRAS* codon 13 mutation is more common (about one third) than codon 12 and 61\[[@B64]\]. However many other studies have not detected any mutations in this gene\[[@B65],[@B66]\]. Any activating point mutations in *KRAS* oncogene can give rise to abnormal growth signals which is one of the hallmarks of cancer. The previous reports have co-related a condition called anomalous arrangement of the pancreatico-biliary duct with presence of gallbladder cancer as patients harboring this condition have a higher frequency of *KRAS* gene mutation as compare to normal condition\[[@B65],[@B67],[@B68]\]. However mutation of *KRAS* gene has never been detected in GBC having adenoma carcinoma sequence of development\[[@B69]\] (Table [2](#T2){ref-type="table"}).

TP53
----

TP53 is a well-known tumor suppressor gene and has various mechanisms of anticancer function and plays significant role in maintenance of genome integrity, apoptosis, genomic stability, and inhibition of angiogenesis etc. Loss of *TP53* function allows deregulated survival of genetically impaired abnormal cells which can lead to neoplastic conversion of later on\[[@B70]\]. *TP53* mutations are relatively more common in later stages of the disease\[[@B63],[@B66],[@B71]-[@B73]\]. Most of the *TP53* mutations associated with GBC are missense mutations that produce a non-functional protein with an increased half-life. The existing literature has reported mutations of the *TP53* gene in between approximately 27% to 70% of gallbladder carcinomas\[[@B74]\]. Many codons of the *TP53* codons are affected by pathogenic mutations of this gene. Functional molecular studies have discovered that mutations in exons 5 and 8 of *TP53* gene causes deregulation of this gene\[[@B75]\]. Details are shown in various existing literature is shown in Table [2](#T2){ref-type="table"}\[[@B54],[@B60],[@B63],[@B64],[@B76]-[@B86]\].

C-ERB-B2
--------

The oncogene *c-erb-B2* is a homologue for epidermal growth receptor, encoding a protein with tyrosine kinase activity. The immunohistochemical expression of c-erb-B2 has been found positive between 10%-46% of gallbladder cases. However its expression has been found to be absent in dysplasia or adenomas as shown by previous reports\[[@B87],[@B88]\]. Animal model studies in transgenic mice have shown that *erbB2* overexpression in the basal layer of the biliary tract epithelium led to the development of GBC in all (100%) of mice. Moreover, the expression of HER2⁄neu was positively observed in 28% of GBCs which was directly correlated with advanced stage of cancer\[[@B89]\]. Therefore, it can be hypothesized that some oncogene is associated with in Gallbladder cancer progression. In a study from India, C-erbB2 was frequently expressed in well differentiated and stage II to stage IV in about 9.4% of GBC cases\[[@B90]\]. A recent report showed HER2/neu overexpression occurred in 14% of the advanced gallbladder cancer cases, and this subgroup was expected to be benefited from HER2/neu pathway inhibitors\[[@B91]\]. Therapeutic targeting of *EGFR/HER2* pathways boosts the anti-proliferative effect of gemcitabine in biliary tract and gallbladder carcinomas as shown by a previous study\[[@B92]\]. Based on facts it can be concluded that *C-ERB-B2* expression can become a marker for a poor prognosis.

HIGH THROUGHPUT MUTATION STUDIES IN GBC
=======================================

High throughput research has made large scale repetition of experiments feasible as it automates the experiments thus it has now become possible to study how all 21000 genes potentially contribute to cell function or disease. But in case of gallbladder cancer there are very limited high throughput studies. One of the pioneer studies published in nature genetics using high throughput approach by Chinese population has found recurrent mutations in ErbB pathway\[[@B93]\]. Javle et al\[[@B94]\] has found 26 missense mutations with more common *TP53* and *PIK3CA* mutations in GBC tumor using NGS technology. Mutation profiling of gallbladder cancer tissue in Indian population has found *PIK3CA* and *KRAS* mutations as most common among this ethnicity\[[@B95]\]. The variability in the results is an indicator of intra-tumoral heterogeneity of cancer, which describes the observation of different tumor cells showing distinct morphological and molecular profiles including variable gene expression but ultimately leading to a common phenotype. The high throughput mutation studies in GBC are presented in Table [3](#T3){ref-type="table"}\[[@B93]-[@B96]\].

GENE EXPRESSION STUDIES IN GBC
==============================

In order to identify potential biomarkers for GBC progression, many studies have been performed to find out the differential gene expression profiles between normal and tumor cells. Existing data various greatly, despite of same grade and stage of the included study subjects. Table [4](#T4){ref-type="table"}\[[@B97]-[@B101]\] and Table [5](#T5){ref-type="table"}\[[@B54],[@B66],[@B75],[@B84],[@B86],[@B90],[@B102]-[@B180]\] are summarizing global and single gene expression studies reported in GBC respectively.

###### 

Summary of single gene expression studied reported in gallbladder cancer

  **Studied single genes**                                                        **Expression pattern**                                                  **Studied population**                          **Ref**.
  ------------------------------------------------------------------------------- ----------------------------------------------------------------------- ----------------------------------------------- ----------------------
  *TP53*                                                                          Expression (20%-70%)                                                    India, Slovenia, Greece, Taiwan, Japan, Chile   \[75,84-86,102-106\]
  *p16*                                                                           Overexpression                                                          South Korea                                     \[107\]
  *FHIT*                                                                          Expression loss (45%-75%)                                               Japan, Chile                                    \[108,109\]
  *ERBB2*                                                                         Overexpression (25%-64%)                                                India, Japan, China, South Korea                \[66,103,110,111\]
  Expressed in 9.4%cases of well differentiated and stage II to stage IV tumors   India                                                                   \[90\]                                          
  *RB*                                                                            20% cases allelic loss                                                  Japan                                           \[54,112\]
  4%-14%- loss of expression                                                                                                                                                                              
  *CDKN1A*                                                                        Reduced expression 49% cases                                            Japan                                           \[113\]
  *Cyclin D1, Cyclin E*                                                           Overexpression (41%-49%)                                                Japan                                           \[114,115\]
  *COX2*                                                                          Over-expressed                                                          Slovenia, Japan, Chile                          \[104,116,117\]
  *BCL2*                                                                          Over-expressed                                                          Japan                                           \[118\]
  *CKIT*                                                                          Expression 45%                                                          Japan                                           \[119\]
  *SOX-4*                                                                         Overexpression                                                          China                                           \[120\]
  *Chemokine (C-X-C motif) ligand 12*                                             Increased expression                                                    South Korea                                     \[121\]
  *CXCR4, CXCR7*                                                                  Increased expression                                                    China                                           \[122\]
  *hedgehog pathway components (Shh, Ptch1 and Gli1)*                             *Shh*: 81.7% of cases expressed                                         China                                           \[123\]
  *Ptch1*: 75.3% of cases                                                                                                                                                                                 
  *Gli1*: 70.0% of cases                                                                                                                                                                                  
  *CD56, CD99*                                                                    Altered expression                                                      South Korea                                     \[124\]
  *CD97, CD55*                                                                    *CD97*: 69.6% of cases expressed                                        China                                           \[125\]
  *CD55*: 65.2% of cases                                                                                                                                                                                  
  *HMGA2 and CD9*                                                                 *HMGA2* positive expression                                             China                                           \[126\]
  *CD9* negative expression                                                                                                                                                                               
  *cholecystokinin type-A*                                                        44.1% of cases expressed                                                India                                           \[127\]
  *vascular endothelial growth factor-A*                                          53.6% of cases expressed                                                China                                           \[128\]
  *VEGF-C, VEGF-D*                                                                *VEGF-C*: 64.0% of cases                                                China                                           \[129\]
  *VEGF-D*: 62.0% of cases                                                                                                                                                                                
  *Tumor endothelial marker 8 protein*                                            Increased expression                                                    India                                           \[130\]
  *L1 cell adhesion molecule*                                                     Increased expression                                                    South Korea                                     \[131\]
  *Tissue factor pathway inhibitor-2*                                             Down-regulated                                                          China                                           \[132\]
  *HIF-1*α                                                                        Increased expression                                                    China                                           \[133\]
  *VHL*                                                                           Reduces expression                                                                                                      
  *ERCC1(excision repair cross-complementing 1)*                                  High expression in best differentiated tumors                           Chile                                           \[134\]
  *NF-E2-related factor 2 (Nrf2)*                                                 Increased expression                                                    China                                           \[135\]
  *CD34 , CA15-3*                                                                 Highly expressed in stroma and in epithelium                            Italy                                           \[136\]
  *ADAM-17*                                                                       Overexpression                                                          China                                           \[137\]
  *Cdx2*                                                                          Aberrant expression                                                     Japan                                           \[138\]
  *TLR4*                                                                          Expressed in glandular and luminal epithelium                           China                                           \[139\]
  *MiRNA*                                                                         Loss of Dicer and Drosha expression                                     China                                           \[140\]
  *Inducible Nitric Oxide Synthase iNOS*                                          Expressed                                                               China                                           \[141\]
  *Prostate stem cell antigen (PSCA)*                                             Down-regulated                                                          Japan, China                                    \[142\]
  *OCT-4*                                                                         Down-regulated                                                          China                                           \[143\]
  *hTERT/Telomerase*                                                              Expressed in 56.66% cases                                               India                                           \[144\]
  *Aquaporins (AQPs)*                                                             Positive expression                                                     Japan                                           \[145\]
  *Ornithine decarboxylase (ODC) and glutamate decarboxylase 65 (GAD65)*          Overexpression                                                          China                                           \[146\]
  *Alpha-methylacyl coenzyme A (racemase) AMACR*                                  Overexpression                                                          Taiwan                                          \[147\]
  *Sonic Hh (Shh)*                                                                Elevated expression                                                     Japan                                           \[148\]
  *TGF-β induced miR-182*                                                         Overexpression                                                          China                                           \[149\]
  *SLP-2*                                                                         Overexpression                                                          China                                           \[150\]
  *TMPRSS4*                                                                       Higher expression                                                       China                                           \[151\]
  *zinc finger X-chromosomal protein*                                             Suppressed                                                              China                                           \[152\]
  *multidrug resistance-associated protein 2 (MRP2)*                              Overexpression                                                          South Korea                                     \[153\]
  *HuR*                                                                           Overexpression                                                          Taiwan                                          \[154\]
  *miR-155*                                                                       Overexpression                                                          Japan                                           \[155\]
  *LAPTM4B-35*                                                                    Overexpressed(76%)                                                      China                                           \[156\]
  *p27, P21*                                                                      *p21* (75% cases) and *p27* (25% cases)                                 Jordan                                          \[157\]
  *Thymidylate synthase (TS)*                                                     Low expression                                                          Japan                                           \[158\]
  *CD146*                                                                         Elevated expression                                                     China                                           \[159\]
  *AEG-1*                                                                         Highly expressed (63.4%)                                                China                                           \[160\]
  *CCKAR*                                                                         Expression increased (76.6%)                                            India                                           \[127\]
  *Nemo-like kinase (NLK)*                                                        Overexpression of *NLK*                                                 China                                           \[161\]
  *C-erbB2*                                                                       Overexpression (9.4%)                                                   India                                           \[90\]
  *Phospho-mTOR expression*                                                       Positive expression (64.1%)                                             Chile                                           \[162\]
  *human telomerase reverse transcriptase (hTERT)*                                Expression increased                                                    India                                           \[163\]
  *Phosphoglycerate kinase 1 (PGK1)*                                              Decreased expression (54.7%)                                            China                                           \[164\]
  *Notch 1 and Notch 3*                                                           Positive expression                                                     China                                           \[165\]
  *CCK-A*                                                                         Decreased expression                                                    India                                           \[166\]
  *3-phosphoinositide-dependent protein kinase 1 (PDK1)*                          Positively expressed                                                    China                                           \[167\]
  *Zinc finger X-chromosomal protein (ZFX)*                                       Overexpression                                                          China                                           \[151\]
  *miR-138*                                                                       Over expression                                                         China                                           \[168\]
  *HSP gp96*                                                                      Expression (90.7%)                                                      China                                           \[169\]
  *Long non-coding RNA-LET*                                                       Overexpression                                                          China                                           \[170\]
  *Survivin*                                                                      higher expression (2.9- fold)                                           India                                           \[171\]
  *Long non-coding RNA CCAT1*                                                     Overexpressed                                                           China                                           \[172\]
  *TEM8*                                                                          Expression increased                                                    India                                           \[130\]
  *Fhit,MIh1, P53*                                                                Reduced expression of Fhit and Mlh1 protein and Overexpression of P53   Japan                                           \[108\]
  *NDRG2, CD24*                                                                   NDRG2 down-regulation, CD24 up-regulation                               China                                           \[173\]
  *IL-6*                                                                          Overexpressed                                                           China                                           \[174\]
  *SLP-2*                                                                         Overexpression                                                          China                                           \[150\]
  *BCL6, p19(ARF)*                                                                *BCL6* overexpression , p19 (ARF) Low Expression                        Taiwan                                          \[175\]
  *VEGF-A*                                                                        High expression of *VEGF-A*                                             Chile                                           \[176\]
  *MALAT1*                                                                        Upregulation of MALAT1                                                  China                                           \[177\]
  *miR-182*                                                                       Upregulation of miR-182                                                 China                                           \[149\]
  *miR-155*                                                                       High expression level of miR-155                                        Japan                                           \[155\]
  *p53, S100A4, p27, p16, RB, Smad4, FHIT, E-cadherin and PML*                    *p53* and *S100A4* overexpressed,                                       South Korea                                     \[178\]
  Loss of p27, p16, RB, Smad4, *FHIT*, E-cadherin and *PML* expression                                                                                                                                    
  *PEG10, TSG101*                                                                 *PEG10* and *TSG101* overexpressed                                      China                                           \[179\]
  *CK7, CK20*                                                                     *CK7* (69.05%), *CK20* (28.57%) expressed                               Greece                                          \[180\]

LOSS OF HETEROZYGOSITY AND MICROSATALLIE INSTABILITY
====================================================

Loss of heterozygosity (LOH) is a common genetic alteration in cancer genome. The events like heterozygous deletion of one of the two alleles, or duplication of a maternal or paternal chromosome or chromosomal region and concurrent loss of the other allele gives rise to LOH. The studies focused to detect loss of heterozygosity (LOH) in GBCs have shown frequent heterozygous allelic loss which spans in 18 different chromosomal regions\[[@B57]\]. Cytogenetic locations involved in frequent loss of heterozygosity *i.e*., 3p, 8p, 9p, and 22q regions have also been identified in GBC from different populations; which have also been reported in several other cancers like Retinoblastoma, melanoma, Squamous cell carcinoma of larynx\[[@B181]-[@B183]\]. In particular, gallbladder tumor shows numerous site of allelic loss in the short arm of chromosome 3, which harbors several known or putative tumor suppressor genes\[[@B109],[@B181]\]. High degree of microsatellite instability (MSI) in 10% of GBC cases was observed as reported in research article published by Goldin et al\[[@B184]\]. A different pattern of allelic loss has also been detected in Japanese population. In this report the allelotype analysis of gallbladder carcinoma revealed an interesting associated with anomalous junction of pancreatico-biliary duct\[[@B68]\]. Table [6](#T6){ref-type="table"}\[[@B54],[@B57],[@B66],[@B68],[@B109],[@B112],[@B185]-[@B193]\] enlists various studies conducted in GBC regarding LOH and MSI.

###### 

Loss of heterozygosity and microsatellite instability studies reported in gallbladder cancer

  **Studied reported in respective population**   **LOH/MSI**                                                                                                                                                  **Ref**.
  ----------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------ -----------------------
  Chilean                                         LOH reported in : 3p, 6q, 7q, 8p, 9p, 9q, 11q, 12q, 17p, 18q, 19p, 22q, and Xq                                                                               \[57\]
  Japan                                           LOH reported in : 2p, 4p, 4q, 8q,9q, 10p,14p,14q,16p, 19p, 21p and Xp \[Maximum deletion- 2p24, 14q22 and 21q22\]                                            \[68\]
  Chilean, Japan                                  p53, 9p.8p, DCC, KRAS, p16, 16q24, 3p,9q, 22q and p161NK4                                                                                                    \[54,66,109,112,185\]
  Greece                                          BAT-26                                                                                                                                                       \[186\]
  Chile, Japan                                    MSI reported (20%-33%)                                                                                                                                       \[187,188\]
  India                                           E-cadherin (CDH1) 2p, 2q, 6q, 7q,17p                                                                                                                         \[189\]
  India                                           Fragile histidine triad (FHIT) MSI-H 17.5% LOH :27.5%                                                                                                        \[190\]
  Japan                                           High incidences of LOH at 1p36 (19/36:53%), 9p21 (12/32:38%), 13q14 (20/36: 56%), 16q24 (31/54: 61%), and 17p13 (15/36: 42%)                                 \[191\]
  Chile                                           FHIT gene locus (3p14.2)                                                                                                                                     \[109\]
  India                                           LOH at 8 loci, that is 3p12, 3p14.2, 5q21, 9p21, 9q, 13q, 17p13, and 18q for tumor suppressor genes (DUTT1, FHIT, APC, p16, FCMD, RB1, p53, and DCC genes)   \[192\]
  India                                           genomic instability at 2p, 2q, 6q, 7q, and 17p loci                                                                                                          \[189\]
  Chile                                           DUTT1 (3p12), FHIT (3p14.2), BLU, RASSF1A, SEMA3B and hMLH1 (3p21.3)                                                                                         \[193\]

LOH: Loss of heterozygosity; MSI: Microsatellite instability.

METHYLATION AND GALLBLADDER CANCER
==================================

Understanding of DNA methylation patterns of gallbladder tumors can prove to be important biomarkers to refine the diagnosis and prognostic information which ultimately helps in appropriate therapeutic selection. Hypermethylation in gene promoter regions is a common epigenetic mechanism for the inactivation of tumor suppressor genes. One of the important research article published previously has found an important link between methylation and survival. In this study methylation of genes *p73, MGMT*, and *DCL1* was significantly associated with survival of gallbladder cancer patients\[[@B194],[@B195]\]. The study was conducted in a series of 109 advanced gallbladder cancer cases. However genes like *CDH13* and *FHIT* did not show any significant tendency with respect to gallbladder cancer patient's survival\[[@B194],[@B195]\]. Multivariate analysis found *MGMT* gene to be an independent prognostic factor for survival found, representing the important role of epigenetic process in gallbladder carcinogenesis\[[@B195]\]. The recent report showed that promoter methylation of specific genes like *CDH1, CDKN2A-p16*, *REPRIMO* (tumor suppressor gene family) and *UCHL1* (also known as PGP9.5) have important role in gallbladder carcinogenesis\[[@B196]\]. Other studies conducted on GBC have shown variable methylation pattern of a number of genes Table [7](#T7){ref-type="table"}\[[@B81],[@B82],[@B193]-[@B208]\].

###### 

Aberrant promoter methylation gene studies summary in gallbladder cancer

  **Gene**                  **Full name**                                                                           **Function**                                                     **Meth Freq**   **Population**                  **Ref**.
  ------------------------- --------------------------------------------------------------------------------------- ---------------------------------------------------------------- --------------- ------------------------------- -------------------------------
  *CDH1*                    Cadherin 1, type 1,                                                                     Tissue invasion (cell-cell adhesion)                             11%-65%         Japan, Chile                    \[194-200\]
  E-cadherin (epithelial)                                                                                                                                                                                                            
  *FHIT*                    Fragile histidine triad gene                                                            Regulation of DNA Replication, and apoptosis                     30%-57%         Chile                           \[81,193-195,199\]
  *APC*                     Adenomatous polyposis coli                                                              Tumor suppressor gene (Cell migration, adhesion and apoptosis)   26%-35%         Chile, United States            \[81,194,195,198,199\]
  *hMLH1*                   Human homologs of                                                                       Mismatch repair                                                  0%-14%          Chile, United States            \[81,193-195,199\]
  MutL gene of bacteria                                                                                                                                                                                                              
  *p16*                     Cyclin-dependent kinase                                                                 Cell cycle regulation                                            15%-60%         Chile, United States, Germany   \[81,82,195,197-199,201,202\]
  inhibitor 2A                                                                                                                                                                                                                       
  *p15*                     Cyclin-dependent kinase inhibitor 2B                                                    Cell cycle regulation                                            22%-44%         Chile                           \[81,198\]
  *DAPK1*                   Death-associated protein kinase 1                                                       Serine-threonine kinase                                          8%-61%          Japan, Chile                    \[81,197,198\]
  *DLC1*                    Deleted in liver cancer 1                                                               GTPase-activating protein                                        39%             Chile                           \[81\]
  *RASSF1*                  RAS association domain family protein 1A                                                Signal transduction                                              0%-36%          Japan, Chile South Korea        \[81,193,197,198,203\]
  *MGMT*                    O-6-methylguanine-DNAmethyltransferase                                                  Methyltransferase                                                13%-30%         Chile, United States            \[81,195\]
  *CDH13*                   CDH13 Cadherin 13, H-cadherin(heart)                                                    Tissue invasion (cell-cell adhesion)                             44%-70%         Chile                           \[81,198\]
  *TIMP3*                   Metallopeptidase inhibitor 3                                                            Degradation of extracellular matrix                              0%-39%          Chile                           \[81,198\]
  *GSTP1*                   Glutathione S-transferase pi 1                                                          Conjugation of hydrophobic and electrophilic compounds           13%             Chile                           \[198\]
  *RARβ2*                   Retinoic acid receptor, beta                                                            Encodes retinoic acid receptor beta                              4%-44%          Chile, United States            \[81,198\]
  *REPRIMO*                 TP53 dependent G2 arrest mediator candidate                                             Cell cycle regulation (p53 mediator)                             62%             Chile                           \[204\]
  *SHP1*                    Protein tyrosine phosphatase,                                                           Regulate cell growth,                                            80%             Chile                           \[198\]
  non-receptor type 6       differentiation, mitotic cycle                                                                                                                                                                           
  *3-OST-2*                 Heparan sulfate (glucosamine)                                                           Osulfotransferase                                                72%             Chile                           \[198\]
  3-O-sulfotransferase 2                                                                                                                                                                                                             
  *RUNX3*                   Runt-related transcription factor 3                                                     TGF-beta signal pathway                                          22%-32%         Chile                           \[197,198\]
  *RIZ1*                    PR domain containing 2, with ZNF domain                                                 Histone/protein methyltransferase                                26%             Chile                           \[198\]
  *HPP1*                    Transmembrane protein with EGF-like and two follistatin-like domains 2                  TGF-beta signal pathway                                          20%                                             \[198\]
  *P73*                     Tumor protein p73                                                                       Induction of apoptosis and cell cycle regulation                 14%-28%         Chile, United States            \[81,198\]
  *SOCS-1*                  Suppressor of cytokine signaling 1                                                      JAK-STAT pathway                                                 12%             Chile                           \[198\]
  *DCR2*                    Tumor necrosis factor receptor superfamily, member 10d                                  TNF-receptor superfamily                                         6%              Chile                           \[198\]
  *SEMA3B*                  Sema domain, immunoglobulin domain (Ig), short basic domain, secreted,(semaphorin) 3B   Induction of apoptosis                                           92%             Chile                           \[193\]
  *DUTT1*                   Human homolog of                                                                        Cell migration and metastasis                                    22%             Chile                           \[193\]
  Drosophila Roundabout                                                                                                                                                                                                              
  (ROBO1)                                                                                                                                                                                                                            
  *BLU*                     Zinc finger, MYND-type containing 10                                                    Cell cycle regulation                                            26%             Chile                           \[193\]
  *p14*                     Ribonuclease P/MRP 14 kDa subunit                                                       Cell cycle regulation                                            40%             Germany                         \[201\]
  *MASPIN*                  Mammary serine protease inhibitor                                                       Tumor suppressor gene                                            70%             India                           \[205\]
  *THBS1*                   Thrombospondin 1                                                                        Platelet aggregation, angiogenesis, and tumorigenesis            52%                                             
  *HLTF*                    Helicase-like transcription factor                                                      Regulate transcription                                           16%                                             
  *MYC*                     V-Myc Avian Myelocytomatosis Viral Oncogene Homolog transcription factor                Cell cycle progression, apoptosis and cellular transformation    80%             Brazil                          \[206\]
  *APC*                     Adenomatous polyposis coli                                                              Tumor suppressor gene                                            71%-95%         Chile                           \[207\]
  *CDKN2A*                  Cyclin-dependent kinase inhibitor 2A                                                    Cell cycle                                                                                                       
  *ESR1*                    Estrogen receptor 1                                                                     Transcription factor                                                                                             
  *PGP9.5*                  Protein gene product 9.5                                                                Neural and/or nerve sheath differentiation                                                                       
  *SSBP2*                   Single-stranded DNA-binding protein 2                                                   Microsatellite instability                                                                                       
  *PGP9.5*                  Protein gene product 9.5                                                                Neural and/or nerve sheath differentiation                       27.2%           South Korea                     \[208\]
  *MLH1, CDKN2A*            MutL homolog 1                                                                          Mismatch repair                                                  5%              Chile                           \[194\]
                            Cyclin-dependent kinase inhibitor 2A                                                    Cell cycle                                                       35%                                             
  *FHIT*                    Fragile histidine triad protein                                                         Purine metabolism                                                21%                                             
  *APC*                     Adenomatous polyposis coli                                                              Tumor suppressor genes                                           25%                                             
  *CDH1*                    Cadherin-1                                                                              Cell cycle                                                       66%                                             

In addition, with the help of advanced technologies like high resolution allele stratification (allelotyping analysis) investigated very high frequencies of 3p (100%), 8p (100%), 9q (88%), 22q (92%) sites in gallbladder cancer that lead to positional identification of tumor suppressor genes associated with GBC malignancies and pathogenesis\[[@B57],[@B58],[@B109],[@B209]\]. Moreover, some well-known tumor suppressor genes that are present in chromosomes like 3p, 5q, 8p,13q and 18q can also influence the gallbladder cancer formation\[[@B57],[@B58],[@B109],[@B209]\].

Candidate genes for gallbladder cancer susceptibility
-----------------------------------------------------

The merely successful mechanism for identifying low or moderate penetrance cancer genes, is the analysis of genes involved in candidate loci. Therefore, these genes are also termed as candidate genes. The candidate gene analysis is done via case-control study, in which allele frequencies in cancer patients and healthy controls are compared and obtained results are analyzed statistically. Candidate modifier genes are selected on the basis of biological plausibility. Most studies are based on genes that encode proteins, thought to be involved in carcinogenesis, such as those involved in apoptosis, cell-cycle control, DNA repair, xenobiotic metabolism, hormonal and inflammatory pathway or other risk factors. Moreover, known genes account for a small proportion of the heritability of gallbladder cancer, and it is likely that many genes with modest effects are yet to be found.

A study by Wang et al\[[@B210]\] from china suggested about CCK-induced impaired gallbladder emptying in patients having gallstones. Most of the candidate genes identified so far are related to the classical rate limiting enzymes and proteins of lipid metabolism, steroidogenesis, lipid transport, bile acid synthesis, bile canalicular transport, gallbladder contractility, cell cycle, DNA repair and Inflammatory pathway\[[@B211]-[@B233]\]. Till now there are very limited studies in GBC which are independently replicated which includes *OGG1*~rs1052133~, *TP53*~rs1042522~, *GSTM1* null polymorphism and *CYP1A1*~rs1048943~ polymorphism\[[@B48]\]. No definitive conclusions can be drawn due to limited number of studies. Hence there is a great need to explore genes related to GBC susceptibility. Table [8](#T8){ref-type="table"}\[[@B30],[@B214]-[@B273]\] shows an overview of candidate gene studies reported in GBC.

###### 

Candidate gene studies (low susceptibility genes) in gallbladder cancer

  **Pathway involved**                         **Gene**                                                                 **Polymorphism**                                                                       **Population**    **Ref**.
  -------------------------------------------- ------------------------------------------------------------------------ -------------------------------------------------------------------------------------- ----------------- -------------
  DNA repair pathway genes                     *XPC*                                                                    (rs2228000) Ala499Val                                                                  China             \[236\]
  (rs2228001) Lys939Gln                        China                                                                                                                                                                             
  *ERCC2*                                      (rs1799793) Asp312Asn                                                    North Indian                                                                           \[232\]           
  (rs13181) Lys751Gln                          North Indian                                                                                                                                                                      
  *MSH2*                                       (rs2303426) IVS1+9G\>C                                                                                                                                                            
  (rs2303425) -118T\>C                                                                                                                                                                                                           
  *OGG1*                                       (rs2072668) 748-15C\>G                                                                                                                                                            
  *TP53*                                       (rs1042522) Pro72Arg                                                     Chilean, Hungary, Japanese                                                             \[237-239\]       
  *XRCC1*                                      (rs1799782) Arg194Trp                                                    North Indian Shanghai, China                                                           \[222,231\]       
  (rs25487) Arg399Gln                                                                                                                                                                                                            
  *APEX1*                                      (rs3136820) Asp148Glu                                                    Shanghai, China                                                                        \[222\]           
  *RAD23B*                                     (rs1805335) IVS5-15A\>G                                                  \[223\]                                                                                                  
  (rs1805329) EX7+65C\>T                                                                                                                                                                                                         
  *FEN1*                                       FEN1-69G\>A and haplotypes                                               China                                                                                  \[240\]           
  Hormonal pathway genes                       *CCKAR*                                                                  (rs1800857) IVS1-5T\>C                                                                 North Indian      \[227\]
  *CCK and CCKAR*                              (rs2071011G\>C, rs915889C/T, rs3822222C/T, rs1800855T/A                  Shanghai, China,                                                                       \[241\]           
  *ESR1*                                       (rs2234693) IVS1-397T\>C                                                 Shanghai, China, North India                                                           \[241-243\]       
  (rs3841686) IVS5-34-\>T                                                                                                                                                                                                        
  (rs2228480) Ex8+229G\>A                                                                                                                                                                                                        
  (rs1801132) Ex4-122G\>C                                                                                                                                                                                                        
  (rs9340799) IVS1-351A\>G                                                                                                                                                                                                       
  *ESR2*                                       (rs1256049) Val328Val                                                    Shanghai, China                                                                                          
  *PGR*                                        Ins/Del                                                                  North India                                                                                              
  *AR*                                         (CAG)n                                                                   Shanghai, China                                                                        \[244\]           
                                               (rs4633) His62His                                                        Shanghai, China                                                                        \[224\]           
  *COMT*                                       (rs4818) Leu136Leu                                                                                                                                                                
  *CYP1A1*                                     (rs2606345) IVS1+606G\>T                                                                                                                                                          
  *CYP1B1*                                     (rs10012)Arg48Gly                                                                                                                                                                 
                                               (rs1065778) IVS4-76A\>G                                                  Shanghai, China                                                                        \[224\]           
  *CYP19A1*                                    (rs700518) Val80Val                                                                                                                                                               
                                               (rs2304463) IVS7-106T\>G                                                                                                                                                          
                                               (rs700519) Arg264Cys                                                                                                                                                              
                                               (rs1065779) IVS9-53G\>T                                                                                                                                                           
                                               (rs4646) Ex11+410G\>T                                                                                                                                                             
  *HSD3B2*                                     (rs1819698) Ex4-133C\>T                                                  Shanghai, China                                                                        \[224\]           
  (rs1361530) Ex4-88C\>G                                                                                                                                                                                                         
  *HSD17B3*                                    (rs2066479) Gly289Arg                                                                                                                                                             
  *HSD17B1*                                    (rs2830) Ex1-486G\>A                                                                                                                                                              
  *SHBG*                                       (rs6259) Ex8+6G\>A                                                                                                                                                                
  *SRD5A2*                                     (rs523349) Ex1-17G\>C                                                                                                                                                             
  *RXR-a*                                      (rs1536475) IVS6+70A\>G                                                  Shanghai, China                                                                        \[245\]           
  (rs1805343) IVS1-27A\>G                                                                                                                                                                                                        
  *RXR-b*                                      (rs2744537) G392T                                                                                                                                                                 
  (rs2076310) C51T                                                                                                                                                                                                               
  *INS*                                        (rs689) A-6T                                                             Shanghai, China                                                                        \[245\]           
  *PPARD*                                      (rs2016520) Ex4+15C\>T                                                   Shanghai, China                                                                                          
  *PPARG*                                      (rs3856806) His477His                                                    Shanghai, China                                                                                          
  Inflammatory pathway genes                   *CR1*                                                                    (rs2274567) His1208Arg                                                                 North Indian      \[230\]
                                               ( rs12144461) Intron 27, HindIII                                                                                                                                                  
  *IL1RN*                                      86-bp VNTR                                                               North Indian                                                                           \[220\]           
                                               (rs689466) -1195G\>A                                                     \[233\]                                                                                                  
  *PTGS2*                                      (rs20417) -765G\>C                                                                                                                                                                
                                               (rs5275) +8473T\>C                                                       North Indian Shanghai, China                                                           \[233,246\]       
  *IL1B*                                       (rs16944) -1060T\>C                                                      Shanghai, China north Indian                                                           \[220,247\]       
  *IL10*                                       rs1800871)- 7334T\>C                                                     Shanghai                                                                               \[247\]           
  (rs1800872) -6653A\>C                        Shanghai                                                                                                                                                                          
  *IL-8*                                       (rs10805066) IL8 -13985C\>G                                              China                                                                                  \[248\]           
  *EGF*                                        (rs4444903) +61A\>G                                                      North Indian                                                                           \[221\]           
  *TGFb1*                                      (rs1800469)-509C\>T                                                      Shanghai, north Indian                                                                 \[219,221,247\]   
  *TNF-*α                                      (rs1800629) -308G\>A                                                                                                                                                              
  *IL6*                                        (rs1800795) 236C\>G)                                                                                                                                                              
  *IL8*                                        (rs10805066) -13985C\>G                                                  China                                                                                  \[248\]           
                                               *MMP-2*                                                                  (rs2285053) -735 C\>T                                                                  North Indian      \[249\]
  (rs9340799) -1306 C\>T                                                                                                                                                                                                         
  *MMP-7*                                      (rs11568818) -181 A\>G                                                                                                                                                            
                                               (rs2250889) P574R                                                                                                                                                                 
  *MMP9*                                       (rs 17576) R279Q                                                                                                                                                                  
                                               (rs 17577) R668Q                                                                                                                                                                  
  *TIMP2*                                      (rs8179090) -418 G\>C                                                                                                                                                             
  Metabolic pathway genes                      *MTHFR*                                                                  (rs1801133) Ala222Val                                                                  Indian            \[228\]
  *APOB*                                       (rs17240441) 35_43del9                                                   Indian                                                                                 \[217\]           
  *NAT2*                                       (rs1799929) NAT2\*5A                                                     Indian                                                                                 \[216\]           
  (rs1799930) NAT2\*6B                                                                                                                                                                                                           
  rs1799931, NAT2\*7A                                                                                                                                                                                                            
  *GSTT1*                                      Null polymorphism                                                        Indian                                                                                 \[215\]           
  *GSTP1*                                      (rs1695) Ile105Val                                                                                                                                                                
  *CYP17*                                      (rs743572) Ex1+27T\>C                                                    Shanghai Indian (265)                                                                  \[250,251\]       
  *GSTM1*                                      Null polymorphism                                                        Indian, Chilean Hungary Japanese                                                       \[215,237,238\]   
  *CYP1A1*                                     (rs4646903) CYP1A1\*2A                                                   Indian, Chilean Hungary Japanese                                                       \[218,237,239\]   
  (rs1048943) Ile462Val (\*2C)                 China, Chilean, Hungary Japanese                                         \[224,237-239\]                                                                                          
  *Cyp1a1 cyp1b1*                              CYP1A1-MspI, CYP1A1-Ile462Val, and CYP1B1-Val432Leu                      India                                                                                  \[252\]           
                                               (rs5930) EX10+55G\>A                                                     Shanghai                                                                               \[253\]           
  *LDLR*                                       (rs6413504) IVS17_42A\>G                                                 Shanghai                                                                                                 
                                               (rs14158) EX18+88G\>A                                                                                                                                                             
  *LPL*                                        (rs263) IVS5-540C\>T                                                                                                                                                              
  *ALOX5*                                      (rs2029253) IVS3+100G\>A                                                                                                                                                          
  *ApoB*                                       rs693) Thr2515Thr                                                        Indian Chilean                                                                         \[30,217\]        
  *ABCG8*                                      (rs11887534) Asp19His                                                    North Indian Shanghai China                                                            \[229,254\]       
  *CETP*                                       (rs708272) TaqIB                                                         Chilean Shanghai China                                                                 \[30,254\]        
  (rs1800775) -629C\>A                         Shanghai China                                                           \[254\]                                                                                                  
  *LRPAP1*                                     (rs11267919)752_177_752_176 I 37                                         North Indian Shanghai China                                                            \[214,254\]       
  *CYP7A1*                                     (rs3808607) -204 A\>C                                                    North Indian                                                                           \[255\]           
  *CYP7A1*                                     (rs3824260) -469 T\>C                                                    North Indian                                                                                             
  *CYP17*                                      (rs743572)A/G                                                            North Indian                                                                           \[250,251\]       
  *ApoB*                                       (rs676210) Pro2739Leu                                                    Shanghai                                                                               \[253\]           
  (rs673548) IVS23-79T\>C                                                                                                                                                                                                        
  rs520354) IVS6+360C \> T                                                                                                                                                                                                       
  (rs1367117) Thr98Ile                                                                                                                                                                                                           
  (rs440446) IVS1+69C\>G                                                                                                                                                                                                         
  *CYP2C19*                                    (rs4244285) CYP2C19\*2,                                                  Japanese                                                                               \[256\]           
  (rs4986893) CYP2C19\*3                                                                                                                                                                                                         
  *ADRB3*                                      (rs4994)A/G                                                              North Indian                                                                           \[257\]           
  Apoptosis pathway                            *CASP8*                                                                  (rs3834129) -652 6N ins/del                                                            North Indian      \[258\]
  (rs1045485) Asp302His                                                                                                                                                                                                          
  (rs3769818 A) IVS12-19 G\>A                                                                                                                                                                                                    
  Nuclear Receptors                            *Lxr-alpha, Beta*                                                        LXR-α (rs7120118) and LXR-β (rs35463555 and rs2695121)                                 North Indian      \[259\]
  Cancer Stem cell gene                        *CD44*                                                                   CD44 (rs13347) C\>T, CD44 (rs353639)A\>C, CD44 (rs187116) G\>A, CD44 (rs187115) T\>C   North Indian      \[260\]
  *NANOG, ALCAM, EpCAM, SOX-2, OCT-4, NANOG*   NANOG (rs11055786)T\>C,                                                  North Indian                                                                           \[261\]           
  ALCAM (rs1157)G\>A                                                                                                                                                                                                             
  EpCAM (rs1126497)T\>C,                                                                                                                                                                                                         
  SOX-2(rs11915160)A\>C                                                                                                                                                                                                          
  OCT-4 (rs3130932)T\>G,                                                                                                                                                                                                         
  NANOG (rs11055786)T\>C                                                                                                                                                                                                         
  Prostate stem cell antigen                   *PSCA*                                                                   (rs2294008) T/C and rs2978974)                                                         India, Japan      \[262,263\]
  miRNA                                        *hsa-miR-146a*                                                           (rs2910164) G\>C                                                                       North Indian      \[264\]
  *hsa-mir-196a2*                              (rs11614913) C\>T                                                                                                                                                                 
  *hsa-mir-499*                                (rs3746444)T\>C                                                                                                                                                                   
  *miR-27,miR-570,miR-181*                     miR-27a (rs895819)A\>G,                                                  North Indian population                                                                \[265\]           
  miR-570(rs4143815)G\>C,                                                                                                                                                                                                        
  miR-181a(rs12537)C\>T                                                                                                                                                                                                          
  GWAS-associated genes                        *DCC*                                                                    (rs7504990)C\>T                                                                        Japan             \[234\]
  ( rs2229080) C\>G                            North Indian                                                             \[235\]                                                                                                  
  (rs4078288) A\>G                                                                                                                                                                                                               
  (rs7504990) C\>T                                                                                                                                                                                                               
  (rs714) A\>G                                                                                                                                                                                                                   
  Wnt signaling pathway                        *SFRP4, DKK2, DKK3, APC, AXIN-2, Β-CATENIN, GLI-1*                       SFRP4 (rs1802073) G\>T,                                                                North Indian      \[266\]
  DKK2 (rs17037102) C\>T                                                                                                                                                                                                         
  DKK3 (rs3206824) C\>T,                                                                                                                                                                                                         
  APC (rs4595552)A/T                                                                                                                                                                                                             
  APC ( rs11954856) G\>T,                                                                                                                                                                                                        
  AXIN-2 (rs4791171)C\>T                                                                                                                                                                                                         
  β-CATENIN (rs4135385) A\>G,                                                                                                                                                                                                    
  GLI-1(rs222826) C\>G                                                                                                                                                                                                           
  Other genes                                  *KRAS*                                                                   codon 25 Gln25His                                                                      Eastern India     \[267\]
  *ACE I/D*                                    (rs4646994) 289 bp del                                                   North Indian                                                                           \[268\]           
  *DNMT3B*                                     (rs1569686) -579 G\>T                                                    North Indian                                                                           \[269\]           
  *TLR2*                                       -196-174del                                                              North Indian                                                                           \[270\]           
  *TLR4*                                       (rs4986791) Thr399Ile                                                    North Indian                                                                                             
  *Adrenergic receptors (ADRA)*                ADRA2A C-1291G, ADRβ3 T190C or Trp64Arg, and ADRβ1 C1165G or Arg389Gly   North Indian                                                                           \[271\]           
  *Death Receptors and their ligands (DR4)*    DR4 (rs20575, rs20576 and rs6557634), FAS (rs2234767) FASL (rs763110)    North Indian                                                                                             
  *PlCE1*                                      (rs2274223) A\>G and. (rs7922612) T\>C                                   North Indian                                                                           \[272\]           
  *Vitamin D receptor (VDR)*                   FokI C\>T                                                                China                                                                                  \[273\]           

The only one genome-wide association study conducted in gallbladder cancer identified a SNP (rs7504990) in *DCC* gene which was associated with six times gallbladder cancer risk in the Japanese population. It has also been reported that reduced expression of *DCC* gene (deleted in colorectal cancer, 18q21.3) was designated to be associated with the greater aggressiveness of the disease which include increased proliferation, poorly differentiated histology, and metastasis through loss of adhesiveness\[[@B234]\]. However genome wide association study (GWAS) identified SNPs was replicated in Indian population and the study found no individual association of *DCC*~rs7504990~ but haplotype analysis of *DCC* gene found the cumulative effect of G~rs2229080~-A~rs4078288~-C~rs7504990~ A~rs714~ haplotypes in Gallbladder Cancer predisposition\[[@B235]\].

Molecular pathogenesis of GBC
-----------------------------

Gallbladder carcinoma develops through a serious of events before converting in to invasive malignancy. Any exposure to carcinogens may convert normal gallbladder epithelium to condition called metaplasia which subsequently forms dysplasia to carcinoma *in situ* (CIS), and finally proceeding to invasive carcinoma in about 15 years\[[@B274],[@B275]\]. The multistage pathogenesis of gallbladder carcinoma begins with gallstones giving rise to a condition called chronic cholecystitis, which increases to risk to gallbladder cancer formation. More than 90% of patients with gallbladder carcinoma show dysplasia and CIS\[[@B274],[@B275]\]. There is an unusual asymmetric thickening of the gallbladder wall with infiltration to surrounding structures in gallbladder cancer. Maximum cases reported in carcinomas of gallbladder are adenocarcinomas (80%-95%). Adenocarconomas can further be of papillary, tubular, mucinous, or signet cell type. Some other types which are present in very low frequency include: squamous cell carcinoma (16%), undifferentiated or anaplastic carcinoma (2%-7%), and adeno-squamous carcinoma (1%-4%)\[[@B276]\]. Most of GBCs (60%) are found in the fundus, near about 30% in the body, and 10% in the neck region.

Tumor markers in GBC
--------------------

Till date there is no reliable tumor marker developed which can be employed in diagnosis of gallbladder cancer. The only two markers *i.e*., carcino-embryonic antigen (CEA) and carbohydrate antigen 19-9 are most often elevated in advanced stages with a low specificity. So most often they are not used in stand-alone diagnosis of GBC\[[@B277]\]. However, there are other tumor markers like CA125, CA199, CEA (carcino-embryonic antigen), cancer antigens (CA) and CA242, which are for diagnosis of different other types of cancer (*e.g*., gastric, liver, pancreatic), have also been researched in diagnosis of gallbladder cancer but the obtained results are highly inconsistent\[[@B278]-[@B280]\]. In addition some previous reports have shown CA 242, RCAS1 (receptor binding cancer antigen expressed on SiSo cells) CA15-3, Mac-2BP (macrophage galactose-specific lectin-2 binding protein), Fragments of cytokeratin-19 (CYFRA 21-1) are frequently present in blood of cancer patients and shown to be associated with GBC with variable sensitivity and specificity\[[@B277],[@B281],[@B282]\].

CONCLUSION
==========

Various lines of evidence suggest role for various environmental risk factors in Gallbladder carcinoma. Despite of many articles regarding genetic predisposition of gallbladder cancer there is no established genetic marker. Also, very limited Genome wide association studies (GWAS) have been conducted in gallbladder cancer till now.

The evidence-based model of gallbladder carcinogenesis and its dissemination by Barreto et al\[[@B283]\] serves as a basic platform for elucidation of molecular mechanisms involved in cancer development which based on recent data can be improved by discovery of other signature mutations using high throughput studies. Technological advancement can be helpful more understanding of pathogenic mechanisms underlying neoplastic conversion of gallbladder cancer muscosa. The tumor markers available for diagnosis GBC has also not of very high specificity and not discovered until advanced stage of the disease leading to complexity of the treatment. Exome sequencing of gallbladder cancer tissue has found ERBB pathway as most dysregulated pathway in this disease. Although the studies have been published in highly distinguished journals but they need to be validated before clinical implication. Moreover, limited studies with small sample size are not robust enough to conclude anything. Regardless of improvement in technologies in research field there is no accountable betterment in the prognosis of GBC patients. The future therefore should be engaged towards good quality research focused on early diagnosis and refinement of prognostic information to ultimately improve the management strategies of gallbladder cancer. Present review provides a comprehensive summery of the studies conducted regarding its Epidemiology, Pathogenesis and molecular genetics under a single umbrella. This will be helpful for the researchers to understand the current scenario of research work and how much success we have gained till now. Based on that future research work can be planned in appropriate directions.
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